Molecular biology of myeloma

Clinical and Translational Oncology

Volumn 9, Issue 10, 2007, Pages 618-624

  Gutierrez N C ^a,b   Garcia Sanz R ^a,b   San Miguel, J F ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Cytogenetic abnormalities; Gene expression profiling; Myeloma; Plasma cell

Indexed keywords

B LYMPHOCYTE RECEPTOR; BREAKPOINT CLUSTER REGION PROTEIN; CHIR 258; CYCLIN D; CYCLIN D1; CYCLIN D2; CYCLIN D3; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; CYCLINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANEUPLOIDY; ARTICLE; CHROMOSOMAL INSTABILITY; CHROMOSOME 14Q; CHROMOSOME 16Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MODIFICATION; DNA RECOMBINATION; DOUBLE STRANDED DNA BREAK; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GERMINAL CENTER; HUMAN; KARYOTYPING; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MONOCLONAL GAMMOPATHY OF UNDERTERMINED SIGNIFICANCE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; ONCOGENE; ONCOGENE C MAF; PATHOGENESIS; SOMATIC HYPERMUTATION; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; REVIEW;

CHROMOSOME ABERRATIONS; CYCLINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA;

EID: 38449101566     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0114-4     Document Type: Article

References (58)

1. Kyle RA, Therneau TM, Rajkumar SV et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564-569
2. Kyle RA, Rajkumar SV (2005) Monoclonal gammopathy of undetermined significance. Clin Lymphoma Myeloma 6:102-114
3. Fugmann SD, Lee AI, Shockett PE et al (2000) The RAG proteins and V(D)J recombination: Complexes, ends, and transposition. Annu Rev Immunol 18:495-527
4. Honjo T, Kinoshita K, Muramatsu M (2002) Molecular mechanism of class switch recombination: Linkage with somatic hypermutation. Annu Rev Immunol 20:165-196
5. Papavasiliou FN, Schatz DG (2002) Somatic hypermutation of immunoglobulin genes: Merging me chanisms for genetic diversity. Cell 109[Suppl]:S35-S44
6. González D, van der BM, García-Sanz R et al (2007) Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood (in press)
7. Kuppers R (2005) Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5:251-262
8. Shaffer AL, Rosenwald A, Staudt LM (2002) Lymphoid malignancies: The dark side of B-cell differentiation. Nat Rev Immunol 2:920-932
9. Shapiro-Shelef M, Calame K (2005) Regulation of plasma-cell development. Nat Rev Immunol 5:230-242
10. Bakkus MH, Heirman C, Van Riet I et al (1992) Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80:2326-2335
11. Sahota SS, Leo R, Hamblin TJ et al (1996) Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. Blood 87:746-755
12. Zandecki M, Lai JL, Facon T (1996) Multiple myeloma: Almost all patients are cytogenetically abnormal. Br J Haematol 94:217-227
13. Fonseca R, Barlogie B, Bataille R et al (2004) Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 64:1546-1558
14. Gutierrez NC, Hernandez JM, Garcia JL et al (2001) Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia 15:840-845
15. Sawyer JR, Lukacs JL, Munshi N et al (1998) Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 92:4269-4278
16. Tabernero D, San Miguel JF, Garcia-Sanz R et al (1996) Incidence of chromosome numerical changes in multiple myeloma. Am J Pathol 149:153-161
17. Zhan F, Hardin J, Kordsmeier B et al (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99:1745-1757
18. Kuehl WM, Bergsagel PL (2002) Multiple myeloma: Evolving genetic events and host interactions. Nat Rev Cancer 2:175-187
19. Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23:6333-6338
20. Ronchetti D, Finelli P, Richelda R et al (1999) Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood 93:1330-1337
21. Chesi M, Nardini E, Lim RS et al (1998) The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92:3025-3034
22. Keats JJ, Reiman T, Maxwell CA et al (2003) In multiple myeloma, t(4; 14)(p 16; q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101:1520-1529
23. Santra M, Zhan F, Tian E et al (2003) A subset of multiple myeloma harboring the t(4; 14) (p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 101:2374-2376
24. Chesi M, Nardini E, Brents LA et al (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16:260-264
25. Grand EK, Chase AJ, Heath C et al (2004) Targeting FGFR3 in multiple myeloma: Inhibition of t(4; 14)-positive cells by SU5402 and PD173074. Leukemia 18:962-966
26. Trudel S, Li ZH, Wei E et al (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105:2941-2948
27. Chesi M, Bergsagel PL, Shonukan OO et al (1998) frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91:4457-4463
28. Bergsagel PL, Kuehl WM (2001) Chromosome translocations in multiple myeloma. Oncogene 20:5611-5622
29. Hurt EM, Wiestner A, Rosenwald A et al (2004) Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5:191-199
30. Shaughnessy J Jr, Gabrea A, Qi Y et al (2001) Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 98:217-223
31. Smadja NV, Fruchart C, Isnard F et al (1998) Chromosomal analysis in multiple myeloma: Cytogenetic evidence of two different diseases. Leukemia 12:960-969
32. Fonseca R, Debes-Marun CS, Picken EB et al (2003) The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102:2562-2567
33. Smadja NV, Leroux D, Soulier J et al (2003) Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 38:234-239
34. Mateo G, Castellanos M, Rasillo A et al (2005) Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 11:3661-3667
35. Avet-Louseau H, Daviet A, Sauner S et al (2000) Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 111:1116-1117
36. Fonseca R, Oken MM, Harrington D et al (2001) Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 15:981-986
37. Fonseca R, Blood E, Rue M et al (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101:4569-4575
38. Moreau P, Facon T, Leleu X et al (2002) Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100:1579-1583
39. Avet-Loiseau H, Attal M, Moreau P et al (2007) Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome. Blood 109:3489-3495
40. Gutierrez NC, Castellanos MV, Martin ML et al (2007) Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: T(4; 14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 21:143-150
41. Gutiérrez NC, García JL, Hernández JM et al (2004) Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 104:2661-2666.
42. Pérez-Simón JA, García-Sanz R, Tabernero MD et al (1998) Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood 91:3366-3371
43. Shaughnessy J Jr, Tian E, Sawyer J et al (2003) Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: Early results of total therapy II. Br J Haematol 120:44-52
44. Tricot G, Barlogie B, Jagannath S et al (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250-4256
45. Drach J, Ackermann J, Fritz E et al (1998) Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92:802-809
46. Shaughnessy J (2005) Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kipl and an aggressive clinical course in multiple myeloma. Hematology 10[Suppl 1]:117-126
47. Avet-Loiseau H, Facon T, Daviet A et al (1999) 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 59:4546-4550
48. Fonseca R, Bailey RJ, Ahmann GJ et al (2002) Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 100:1417-1424
49. Avet-Loiseau H, Li JY, Morineau N et al (1999) Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood 94:2583-2589
50. Chng WJ, Van Wier SA, Ahmann GJ et al (2005) A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 106:2156-2161
51. Shou Y, Martelli ML, Gabrea A et al (2000) Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A 97:228-233
52. Liu P, Leong T, Quam L et al (1996) Activating mutations of N-and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 88:2699-2706
53. Neri A, Baldini L, Trecca D et al (1993) p53 gene mutations in multiple myeloma are associated with advance of malignancy. Blood 81:128-135
54. Guillerm G, Gyan E, Wolowiec D et al (2001) p16(INK4a) andp15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 98:244-246
55. Mateos MV, García-Sanz R, López-Pérez R et al (2001) p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. Hematol J 2:146-149
56. Davies FE, Dring AM, Li C et al (2003) Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 102:4504-4511
57. Zhan F, Huang Y, Colla S et al (2006) The molecular classification of multiple myeloma. Blood 108:2020-2028
58. Bergsagel PL, Kuehl WM, Zhan F et al (2005) Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood 106:296-303